Compare3 records
3 records on the same 7 fields; 7 differ.
A rust rule marks a value that differs from most of the others. Fields carry their source quote where one exists.
| Field | NCT07656376↗ Clinical Trial of DN022150 Combined With AG Chemotherapy as First-line Treatment for Locally Advanced or Meta… | NCT07619521↗ Testing the Combination of Anti-Cancer Drugs, Selumetinib and DS-8201a (Trastuzumab Deruxtecan), for Advanced… | NCT07594067↗ TCR1188-ABC Cells in KRAS-mutated Cancers |
|---|---|---|---|
| Phasediffers | Phase 2 / Phase 3 | Phase 1 / Phase 2 | Phase 1 |
| Statusdiffers | Not yet recruiting | Recruiting | Recruiting |
| Enrollmentdiffers | 465 | 31 | 30 |
| Startdiffers | 6 June 2027 | 1 June 2027 | December 2026 |
| Sponsor classdiffers | Industry | Nih | Other |
| Interventiondiffers | Drug: DN022150+AG( Stage I ）; Drug: DN022150+AG（Stage II）; Drug: placebo+AG（Stage II）Drug: DN022150+AG( Stage I ）. 28-day /cycle | Procedure: Biospecimen Collection; Procedure: Diagnostic Imaging Testing; Procedure: Echocardiography Test; Procedure: Multigated Acquisition ScanProcedure: Biospecimen Collection. Undergo blood sample collection | Biological: TCR1188-ABC cells; Drug: Fludarabine + Cyclophosphamide combination; Drug: TocilizumabBiological: TCR1188-ABC cells. TCR1188 modified, base-edited autologous CD4+ and CD8+ T cells expressing TCR1188 and a scFv fragment specific to ILT4 (LILRB2) … |
| Primary endpointdiffers | DLTDLT. stage I ：To evaluate the safety and tolerability of different doses of DN022150 for Injection combined with AG regimen in participants with locally advanc… | Occurrence of dose limiting toxicities (DLTs) (dose escalation phase)Occurrence of dose limiting toxicities (DLTs) (dose escalation phase). Will provide the number and proportion of DLTs provide and 95% confidence intervals. Tim… | Number of Subjects with treatment related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) V6.0Number of Subjects with treatment related adverse events using NCI Common Terminology Criteria for Adverse Events (CTCAE) V6.0. Type, frequency, severity, and … |
Why might these disagree?
- Phase. They are at different phases, so they answer different questions (safety and dose versus efficacy).
- Status. Some are finished and some are not, so not all results exist yet.
- Enrollment. Their sizes differ, which changes how precise any result can be.
- Start. They ran at different times, against different standards of care.
- Sponsor class. Industry and academic sponsors often select patients and endpoints differently.
- Intervention. They test different drugs or combinations.
- Primary endpoint. They measure success differently, so their results are not directly comparable.